Summary:
This prospective longitudinal study examined both short- and long-term changes in health-related quality of life (HRQL) in 52 breast cancer patients with poor prognosis receiving high-dose chemotherapy (HDC) treatment with autologous blood stem cell transplantation (ASCT). HRQL was measured seven times from baseline to 2 years post enrollment with the Functional Living Index-Cancer (FLIC), the EuroQol (EQ-5D), and a quality of life visual analogue scale. The percentage of questionnaires returned at each assessment time ranged from 80 to 92%. All three measures showed a similar pattern of change, with HRQL decreasing following administration of HDC, and returning to baseline levels 8 weeks post HDC. A repeated-measures analysis of variance showed that the FLIC at 2 years was significantly better than baseline (P=<0.0001). Difficulty sleeping, headaches, and decreased sexual interest were the most common symptoms reported in the longer term. Our results have implications for early psychosocial intervention in the care of breast cancer patients with poor prognosis undergoing treatment with HDC and ASCT because such interventions can further improve the quality of their survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Servaes P, Verhagen S, Bleijenberg G . Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 2002; 13: 589–598.
Lindley C, Vasa S, Sawyer WT, Winer EP . Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998; 16: 1380–1387.
Hann DM, Jacobsen PB, Martin SC et al. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer 1997; 5: 44–52.
Carlson LE, Koski T, Gluck S . Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. Bone Marrow Transplant 2001; 27: 989–998.
Ganz PA, Desmond KA, Belin TR et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17: 2371–2380.
Winer EP, Lindley C, Hardee M et al. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology 1999; 8: 167–176.
Hann DM, Jacobsen PB, Martin SC et al. Quality of life following bone marrow transplantation for breast cancer: a comparative study. Bone Marrow Transplant 1997; 19: 257–264.
Macquart-Moulin G, Viens P, Palangie T et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 2000; 18: 754–764.
Van Den Hout WB, Van Der Linden YM, Steenland E et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost–utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222–229.
Trippoli S, Vaiani M, Lucioni C, Messori A . Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19: 855–863.
Stewart DA, Paterson AHG, Ruether JD et al. High dose mitoxantrone, vinblastine, cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective, multicentre study. Annals of Oncology, in press.
Schipper H, Clinch J, McMurray A, Levitt M . Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472–483.
Osoba D . Effect of Cancer on Quality of Life. CRC Press: Boca Raton, FL, 1991.
Brooks R . EuroQol: the current state of play. Health Policy 1996; 37: 53–72.
Uyl-de Groot CA, Vellenga E, De Vries EG et al. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial. Pharmacoeconomics 1997; 12: 351–360.
Dolan P . Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095–1108.
De Boer AG, van Lanschot JJ, Stalmeier PF et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 2004; 13: 311–320.
Stevens J . Applied Multivariate Statistics for the Social Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ, 1986.
Conner-Spady B, Cumming C, Nabholtz JM et al. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 2001; 10: 479–486.
Frick E, Borasio GD, Zehentner H et al. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation. Psychooncology 2004; 13: 116–124.
Ahles TA, Tope DM, Furstenberg C et al. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1457–1462.
Brandberg Y, Michelson H, Nilsson B et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 2003; 21: 3659–3664.
van Agthoven M, Vellenga E, Fibbe WE et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomised trial. Eur J Cancer 2001; 37: 1781–1789.
Ganz PA, Desmond KA, Leedham B et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94: 39–49.
Zabora J, Blanchard C, Smith E et al. Prevalence of psychological distress among cancer patients across the disease continuum. J Psychosocial Oncol 1997; 15: 73–87.
McQuellon RP, Craven B, Russell GB et al. Quality of life in breast cancer patients before and after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 579–584.
Andrykowski MA, Cordova MJ, Hann DM et al. Patients' psychosocial concerns following stem cell transplantation. Bone Marrow Transplant 1999; 24: 1121–1129.
Neitzert CS, Ritvo P, Dancey J et al. The psychosocial impact of bone marrow transplantation: a review of the literature. Bone Marrow Transplant 1998; 22: 409–422.
Hjermstad MJ, Loge JH, Evensen SA et al. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation. Bone Marrow Transplant 1999; 24: 1219–1228.
Irvine DM, Vincent L, Graydon JE, Bubela N . Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs 1998; 21: 127–135.
Rolland J, Massie M . Breast cancer. In: Holland J (ed) Psycho-Oncology. Oxford University Press: New York, 2004 pp 380–401.
Hjermstad M, Holte H, Evensen S et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999; 24: 911–918.
Rogers M, Kristjanson LJ . The impact on sexual functioning of chemotherapy-induced menopause in women with breast cancer. Cancer Nurs 2002; 25: 57–65.
Degner LF, Kristjanson LJ, Bowman D et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997; 277: 1485–1492.
Roche H, Viens P, Biron P et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003; 10: 42–47.
Curran D, Bacchi M, Schmitz SF et al. Identifying the types of missingness in quality of life data from clinical trials. Stat Med 1998; 17: 739–756.
Dicato M . High-dose chemotherapy in breast cancer: where are we now? Semin Oncol 2002; 29: 16–20.
Acknowledgements
We thank Jan McLaughlin for data collection and management. Grant support: Alberta Cancer Foundation: Autologous Transplant Program Account, TBCC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Conner-Spady, B., Cumming, C., Nabholtz, JM. et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 36, 251–259 (2005). https://doi.org/10.1038/sj.bmt.1705032
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705032
Keywords
This article is cited by
-
The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression
Health and Quality of Life Outcomes (2022)
-
Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Bone Marrow Transplantation (2017)
-
EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre
The Patient - Patient-Centered Outcomes Research (2017)
-
Targeted drugs and Psycho-oncological intervention for breast cancer patients
Journal of Negative Results in BioMedicine (2016)
-
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
PharmacoEconomics (2015)